Alcobra tumbles on Phase III ADHD results for metadoxine
This article was originally published in Scrip
Alcobra's stock value was cut in half and then some on 6 October after the company revealed highly anticipated results from the first Phase III clinical trial for extended-release metadoxine (MDX) in the treatment of attention deficit hyperactivity disorder (ADHD).
You may also be interested in...
Failing to meet the primary endpoint in its second Phase III study in adult ADHD, the Israeli firm confirms there is no path forward in that indication. Developing MDX for Fragile X syndrome and business development options are under consideration.
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.